Abstract
High-throughput screening identified compound 1 as a potent P2X(7) receptor antagonist suitable for lead optimisation. Structure-activity relationships (SAR) of a series of (1H-pyrazol-4-yl)acetamides were investigated and compound 32 was identified as a potent P2X(7) antagonist with enhanced potency and favourable physicochemical and pharmacokinetic properties.
Copyright 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Acetamides / chemical synthesis
-
Acetamides / chemistry*
-
Acetamides / pharmacokinetics
-
Administration, Oral
-
Animals
-
Anti-Infective Agents / chemical synthesis*
-
Anti-Infective Agents / chemistry
-
Anti-Infective Agents / pharmacokinetics
-
High-Throughput Screening Assays
-
Humans
-
Injections, Intravenous
-
Purinergic P2 Receptor Antagonists*
-
Pyrazoles / chemical synthesis*
-
Pyrazoles / chemistry
-
Pyrazoles / pharmacokinetics
-
Rats
-
Receptors, Purinergic P2 / metabolism
-
Receptors, Purinergic P2X7
-
Structure-Activity Relationship
Substances
-
Acetamides
-
Anti-Infective Agents
-
P2RX7 protein, human
-
Purinergic P2 Receptor Antagonists
-
Pyrazoles
-
Receptors, Purinergic P2
-
Receptors, Purinergic P2X7